A study from Liu et al. revealed somatic KMT2D mutations in about 19% of patients suffering from diffuse large B cell lymphoma (DLBCL) promoting tumor progression (Liu Q. X. et al., 2024). The gene discussed is KMT2D; the disease is neoplasm.